Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term immunotherapy. Found 31 abstracts

no pagination
Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer. 2020 Jan 15;126(2):260-70.
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Molecular therapy : the journal of the American Society of Gene Therapy. 2020 Feb 05;28(2):548-60.   PMCID: PMC7001088
Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA. Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best practice & research Clinical endocrinology & metabolism. 2019 Dec 12;:101371.
Reck M, Borghaei H, O'Byrne KJ. Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncol. 2019 Jul;15(19):2287-302.
Wissler HL, Ehlerding EB, Lyu Z, Zhao Y, Zhang S, Eshraghi A, Buuh ZY, McGuth JC, Guan Y, Engle JW, Bartlett SJ, Voelz VA, Cai W, Wang RE. Site-Specific Immuno-PET Tracer to Image PD-L1. Molecular pharmaceutics. 2019 May 06;16(5):2028-36.   PMCID: PMC6521698
Abbosh PH, Plimack ER. Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2018 Jan 20;4(1):9-18.   PMCID: PMC5798524
Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncol. 2018 Jun;14(14):1409-21.
Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic advances in medical oncology. 2018 Jul;10:1758835918788310.   PMCID: PMC6066800
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LM, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Apr 12;33(5):843-852 e4.   PMCID: PMC5953836
Marty Pyke R, Thompson WK, Salem RM, Font-Burgada J, Zanetti M, Carter H. Evolutionary Pressure against MHC Class II Binding Cancer Mutations. Cell. 2018 Oct 04;175(2):416-428e13.   PMCID: PMC6482006
Marty R, de Prisco N, Carter H, Font-Burgada J. MHC-I genotype drives early immune selection of oncogenic mutations. Molecular & cellular oncology. 2018 Jan;5(2):e1409863.   PMCID: PMC5821412
Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. Journal of thoracic disease. 2018 Feb;10(Suppl 3):S480-S489.   PMCID: PMC5861268
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr;123(7):1259-71.   PMCID: PMC5705038
Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the Website. Kidney cancer. 2017 Nov 27;1(2):151-9.   PMCID: PMC6179107
Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, Carter H. MHC-I Genotype Restricts the Oncogenic Mutational Landscape. Cell. 2017 Nov 30;171(6):1272-1283 e15.   PMCID: PMC5711564
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017 Jul;28(7):1436-47.   PMCID: PMC5834038
Jochems C, Hodge JW, Fantini M, Fujii R, Morillon Ii YM, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016 Dec 27;7(52):86359-73.   PMCID: PMC5341330
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.
Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016 Jun;8(7):785-98.
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term immunotherapy

immunotherapy cancer Pd-1 methods Immunotherapy Ctla-4 bladder cancer immunology therapy kidney cancer cancer susceptibility prediction cancer predisposition neoantigens Combined Modality Therapy biomarkers major histocompatibility complex non-small-cell lung cancer Pd-l1 urothelial carcinoma clinical trials human leukocyte antigen antigen presentation Neoplasms Head and Neck Neoplasms Monoclonal Antibodies Neoadjuvant Therapy adverse effects interest organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those pembrolizumab neoadjuvant chemotherapy immunoediting DNA damage response tumor evolution molecular oncology adrenal insufficiency checkpoint blockade Immunologic Factors ovarian cancer Mutation checkpoint inhibitors Adcc repair tumor mutational burden (TMB) Retrospective Age Factors AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb cytotoxic T-lymphocyte associated protein 4 Targeted therapy CD4-Positive T-Lymphocytes Mhc-ii CAR T cell therapy immune checkpoint inhibitors head and neck cancer prostate cancer site-specific toxicities CD8-Positive T-Lymphocytes lymphoma genitourinary cancer pathology mortality Clinical Trials as Topic Tmb Misr2 lung cancer Molecular Evolution tumor mutational burden chemotherapy high affinity CD16 Patient Selection chemoresponse response criteria etiology Histocompatibility Antigens Class I genetics Treatment Outcome ipilimumab immune checkpoint atezolizumab checkpoint inhibitor disclosed No writing assistance was utilized in the production of this waterfall plots Misrii The authors have no other relevant affiliations or financial involvement with any Urinary Bladder Neoplasms precision medicine Fdg-pet mutation burden NK lysis institutionally directed clinical trial support from Horizon Pharma ER Plimack immune editing Amhr2 chimeric antigen receptor pituitary human papillomavirus neoadjuvant programmed death 1 United States cytokine oncogenes National Cancer Institute (US) autoimmunity Eli Lilly has served on advisory boards and as consultant for Genentech Histocompatibility Antigens Class II upper tract urothelial carcinoma diagnosis predictive biomarker antibody hypophysitis Neoplasm Antigens Molecular Targeted Therapy unnatural amino acid Vegf programmed death ligand 1 (PD-L1) adjuvant targeted therapy T cells immunity cisplatin Checkpoint inhibitors mullerian inhibiting substance type 2 receptor Neoplasm Staging therapeutic use driver mutations immune checkpoint blockade Misiir Fox Chase Cancer Center renal cell carcinoma immunoediting immunology cetuximab nivolumab Pfizer and Bristol-Myers Squibb and has received institutionally Novartis Neoplasm Metastasis manuscript positron emission tomography
Last updated on Wednesday, July 08, 2020